Sensitive detection of actionable variants is essential to help potentially monitor disease and inform decisions. We present new data on multiplex digital PCR assays designed for circulating tumor DNA, enabling detection down to 0.1% variant allele frequency. Targets include ESR1, BRAF, PIK3CA, EGFR, and KRAS, key research biomarkers for therapy selection and resistance monitoring. Performance data will be shared for ESR1 and BRAF assays, highlighting analytical sensitivity and workflow compatibility. This workshop will discuss how multiplex dPCR can complement existing sequencing approaches, providing rapid and cost-effective solutions for molecular pathology research laboratories.
